Diagnosis of hypogonadism in ageing men.


Journal

Reviews in endocrine & metabolic disorders
ISSN: 1573-2606
Titre abrégé: Rev Endocr Metab Disord
Pays: Germany
ID NLM: 100940588

Informations de publication

Date de publication:
12 2022
Historique:
accepted: 10 10 2022
pubmed: 11 11 2022
medline: 28 12 2022
entrez: 10 11 2022
Statut: ppublish

Résumé

To make the diagnosis of hypogonadism in an ageing man, in absence of rare organic cause often referred to as functional or late onset hypogonadism (LOH), he should present with a clinical syndrome suggestive of androgen deficiency and have consistently low serum testosterone (T) levels. This does not differ from the diagnosis of any other form of hypogonadism. Particular to LOH diagnostic are uncertainties surrounding this entity: signs and symptoms of androgen deficiency (including sexual symptoms) are nonspecific in older men; clinical significance of only moderately low T levels is uncertain; comorbidity plays a substantial role with potential for reversibility; the place of T therapy in these men is debatable. This context demands for a pragmatic, but appropriately conservative approach to diagnosis. Evaluation should be stepwise with clinical evaluation, if suggestive for androgen deficiency, followed by measurement of a fasting morning serum T, if unequivocally low to be confirmed in a separate morning sample by a second low T or, if initial T borderline low or in presence of factors known to affect SHBG, by a low calculated free T level. All other (free) T results make hypogonadism an unlikely cause of the patient's symptoms. In the absence of consensus cut-off levels for total and free T in the published clinical guidelines for diagnosis of hypogonadism, it seems appropriate in the context of LOH to use stringent criteria indicating a convincingly low serum T. The approach to the diagnosis of LOH is not fundamentally different from that of other forms of hypogonadism but should put extra weight on prioritizing the shunning of overdiagnosis above the risk of underdiagnosis.

Identifiants

pubmed: 36355322
doi: 10.1007/s11154-022-09763-4
pii: 10.1007/s11154-022-09763-4
doi:

Substances chimiques

Testosterone 3XMK78S47O
Androgens 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1139-1150

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Matsumoto AM, Bremner WJ. Testicular disorders. In: Melmed S, Polansky KS, Larsen PR, KronenbergHM, editors. Williams Textbook of Endocrinology. 13th edition. New York, NY: Elsevier; 2016. pp. 688–777.
Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur J Endocrinol. 2008;159:507–14.
doi: 10.1530/EJE-08-0601
Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103:1715–44.
doi: 10.1210/jc.2018-00229
Yeap BB, Grossmann M, McLachlan RI, Handelsman DJ, Wittert GA, Conway AJ, Stuckey BG, Lording DW, Allan CA, Zajac JD, Burger HG. Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy. Med J Aust. 2016;205:173–8.
doi: 10.5694/mja16.00393
Corona G, Goulis DG, Huhtaniemi I, Zitzmann M, Toppari J, Forti G, Vanderschueren D, Wu FC. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males. Andrology. 2020;8:970–87. https://doi.org/10.1111/andr.12770 .
doi: 10.1111/andr.12770
Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, Lightner DJ, Miner MM, Murad MH, Nelson CJ, Platz EA, Ramanathan LV, Lewis RW. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200:423–32. https://doi.org/10.1016/j.juro.2018.03.115 .
doi: 10.1016/j.juro.2018.03.115
Salonia A, Bettocchi C, Carvalho J, Corona G, Jones TH, Kadioglu A, Martinez-Salamanca JI, Minhas S, Serefoglu EC, Verze P. EAU guidelines on Sexual and Reproductive Health. European Association of Urology 2020. https://uroweb.org/guideline/sexual-and-reproductive-health/ Accessed 19 Oct 2020.
Jayasena CN, Anderson RA, Llahana S, Barth JH, MacKenzie F, Wilkes S, Smith N, Sooriakumaran P, Minhas S, Wu FC, Tomlinson J, Quinton R. Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clin Endocrinol (Oxf). 2022;96:200–19.
doi: 10.1111/cen.14633
Morgentaler A, Traish A, Hackett G, Jones TH, Ramasamy R. Diagnosis and treatment of testosterone deficiency: updated recommendations from the Lisbon 2018 international consultation for sexual medicine. Sex Med Rev. 2019;7:636–49.
doi: 10.1016/j.sxmr.2019.06.003
Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005;26:833–76.
doi: 10.1210/er.2004-0013
Tajar A, Forti G, O’Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FC, EMAS Group. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010;95:1810–8.
doi: 10.1210/jc.2009-1796
Kaufman JM, Lapauw B, Mahmoud A, T’Sjoen G, Huhtaniemi IT. Aging and the Male Reproductive System. Endocr Rev. 2019;40:906–97.
doi: 10.1210/er.2018-00178
Giagulli VA, Castellana M, Lisco G, Triggiani V. Critical evaluation of different available guidelines for late-onset hypogonadism. Andrology. 2020;8:1628–41.
doi: 10.1111/andr.12850
Fode M, Salonia A, Minhas S, Burnett AL, Shindel AW. Late-onset hypogonadism and testosterone therapy – a summary of guidelines from the American Urological Association and the European Association of Urology. Eur Urol Focus. 2019;5:539–44.
doi: 10.1016/j.euf.2019.02.021
Grossmann M, Matsumoto AM. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J Clin Endocrinol Metab. 2017;102:1067–75.
doi: 10.1210/jc.2016-3580
Banica T, Verroken C, Reyns T, Mahmoud A, T’Sjoen G, Fiers T, Kaufman J-M, Lapauw B. Early decline of androgen levels in healthy adult men: an effect of aging per se? A prospective cohort study. J Clin Endocrinol Metab. 2021;106:1074–83.
doi: 10.1210/clinem/dgaa915
Yeap BB, Manning L, Chubb SAP, Handelsman DJ, Almeida OP, Hankey GJ, Flicker L. Progressive impairment of testicular endocrine function in ageing men: testosterone and dihydrotestosterone decrease, and luteinizing hormone increases, in men transitioning from the 8th to 9th decades of life. Clin Endocrinol (Oxf). 2018;88(1):88–95.
doi: 10.1111/cen.13484
Travison TG, Vesper HW, Orwoll E, Wu F, Kaufman JM, Wang Y, Lapauw B, Fiers T, Matsumoto AM, Bhasin S. Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe. J Clin Endocrinol Metab. 2017;102:1161–73.
doi: 10.1210/jc.2016-2935
Araujo AB, Esche GR, Kupelian V, O’Donnell AB, Travison TG, Williams RE, Clark RV, McKinlay JB. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92:4241–7.
doi: 10.1210/jc.2007-1245
Tajar A, Huhtaniemi IT, O’Neill TW, Finn JD, Pye SR, Lee DM, Bartfai G, Boonen S, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Wu FC, EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97:1508–16.
doi: 10.1210/jc.2011-2513
Rosen RC, Araujo AB, Connor MK, Gerstenberger EP, Morgentaler A, Seftel AD, Miner MM, Shabsigh R. The NERI hypogonadism screener: psychometric validation in male patients and controls. Clin Endocrinol (Oxf). 2011;74:248–56.
doi: 10.1111/j.1365-2265.2010.03925.x
Corona G, Mannucci E, Ricca V, Lotti F, Boddi V, Bandini E, Balercia G, Forti G, Maggi M. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int J Androl. 2009;32(6):720–8.
doi: 10.1111/j.1365-2605.2009.00952.x
Travison TG, Morley JE, Araujo AB, O’Donnell AB, McKinlay JB. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab. 2006;91:2509–13.
doi: 10.1210/jc.2005-2508
Millar AC, Lau AN, Tomlinson G, Kraguljac A, Simel DL, Detsky AS, Lipscombe LL. Predicting low testosterone in aging men: a systematic review. CMAJ. 2016;188:E321–30.
doi: 10.1503/cmaj.150262
Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, FinnJD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT, EMAS Group. Identification of late onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123–35.
doi: 10.1056/NEJMoa0911101
Rastrelli G, Corona G, Tarocchi M, Mannucci E, Maggi M. How to define hypogonadism? Results from a population of men consulting for sexual dysfunction. J Endocrinol Invest. 2016;39:473–84.
doi: 10.1007/s40618-015-0425-1
Cunningham GR, Stephens-Shields AJ, Rosen RC, Wang C, Bhasin S, Matsumoto AM, Parsons JK, Gill TM, Molitch ME, Farrar JT, Cella D, Barrett-Connor E, Cauley JA, Cifelli D, Crandall JP, Ensrud KE, Gallagher L, Zeldow B, Lewis CE, Pahor M, Swerdloff RS, Hou X, Anton S, Basaria S, Diem SJ, Tabatabaie V, Ellenberg SS, Snyder PJ. Testosterone treatment and sexual function in older men with low testosterone levels. J Clin Endocrinol Metab. 2016;101:3096–104.
doi: 10.1210/jc.2016-1645
Hyde Z, Flicker L, Hankey GJ, Almeida OP, McCaul KA, Chubb SAP, Yeap BB. Prevalence of sexual activity and associated factors in men aged 75 to 95 years: a cohort study. Ann Intern Med. 2010;153:693–702.
doi: 10.7326/0003-4819-153-11-201012070-00002
Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D, European Male Aging Study Group. Hypothalamic-pituitary-testicular axis disruption in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008;93:2737–45.
doi: 10.1210/jc.2007-1972
Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch, Resnick SM, Budoff M, Mohler ER 3rd, Wenger NK, Cohen HJ, Schrier S, Keaveny TM, Kopperdahl D, Lee D, Cifelli D, Ellenberg SS. Lessons From theTestosterone Trials. Endocr Rev. 2018;39:369–86.
doi: 10.1210/er.2017-00234
Kaufman JM, Lapauw B. Role of testosterone in cognition and mobility of aging men. Andrology. 2020;8:1567–79.
doi: 10.1111/andr.12872
Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov C, Dzekov J, Magliano L, Storer TW. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005;90:678–88.
doi: 10.1210/jc.2004-1184
Andres E, Serraj K, Federici L, Vogel T, Kaltenbach G. Anemia in elderly patients: new insight into an old disorder. Geriatr Gerontol Int. 2013;13:519–27.
doi: 10.1111/ggi.12017
Kaufman JM. Management of osteoporosis in older men. Aging Clin Exp Res. 2020;33:1439–52.
doi: 10.1007/s40520-021-01845-8
Mahmoud AM, Goemaere S, El-Garem Y, Van Pottelbergh I, Comhaire FH, Kaufman JM. Testicular volume in relation to hormonal indices of gonadal function in community-dwelling elderly men. J Clin Endocrinol Metab. 2003;88:179–84.
doi: 10.1210/jc.2002-020408
Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry HM III. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49:1239–42.
doi: 10.1053/meta.2000.8625
Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel C, Hummel W. A new ‘aging males’ symptoms’ rating scale. Aging Male. 1999;2:105–14.
doi: 10.3109/13685539909003173
Moore C, Huebler D, Zimmermann T, Heinemann LA, Saad F, Thai DM. The Aging Males’ Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol. 2004;46:80–7.
doi: 10.1016/j.eururo.2004.01.009
Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf). 2000;53:703–11.
doi: 10.1046/j.1365-2265.2000.01152.x
Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian J Androl. 2012;14:251–9.
doi: 10.1038/aja.2011.138
Corona G, Mannucci E, Petrone L, Balercia G, Fisher AD, Chiarini V, Forti G, Maggi M. ANDROTEST: a structured interview for the screening of hypogonadism in patients with sexual dysfunction. J Sex Med. 2006;3:706–15.
doi: 10.1111/j.1743-6109.2006.00262.x
Hayes RP, Henne J, Kinchen KS. Establishing the content validity of the Sexual Arousal, Interest, and Drive Scale and the Hypogonadism Energy Diary. Int J Clin Pract. 2015;69:454–65.
doi: 10.1111/ijcp.12542
Brock G, Heiselman D, Maggi M, Kim SW, Rodrıguez Vallejo JM, Behre HM, McGettigan J, Dowsett SA, Hayes RP, Knorr J, Ni X, Kinchen K. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. J Urol. 2016;195:699–705.
doi: 10.1016/j.juro.2015.10.083
Gelhorn HL, Dashiell-Aje E, Miller MG, De Rogatis LR, Dobs A, Seftel AD, Althof SE, Brod M, Revicki DA. Psychometric evaluation of the Hypogonadism Impact of Symptoms Questionnaire. J Sex Med. 2016;13:1737–49.
doi: 10.1016/j.jsxm.2016.09.006
Diver MJ, Imtiaz KE, Ahmad AM, Vora JP, Fraser WD. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol. 2003;58:710–7.
doi: 10.1046/j.1365-2265.2003.01772.x
Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab. 1983;56:1278–81.
doi: 10.1210/jcem-56-6-1278
Tenover JS, Matsumoto AM, Clifton DK, Bremmer WJ. Age related alterations in the circadian rhythms of pulsatile luteinizing hormone and testosterone secretion in healthy men. J Gerontol. 1988;43:M163–9.
doi: 10.1093/geronj/43.6.M163
Axelsson J, Ingre M, Akerstedt T, Holmbäck U. Effects of acutely displaced sleep on testosterone. J Clin Endocrinol Metab. 2005;90:4530–5.
doi: 10.1210/jc.2005-0520
Ramage C, Jarrett J, Zimmet P. Fall in plasma-testosterone levels in normal male subjects in response to an oral glucose load. Lancet. 1973;301(7810):967–8.
doi: 10.1016/S0140-6736(73)91601-2
Lehtihet M, Arver S, Bartuseviciene I, Pousette A. S-testosterone decrease after a mixed meal in healthy men independent of SHBG and gonadotrophin levels. Andrologia. 2012;44:405–10.
doi: 10.1111/j.1439-0272.2012.01296.x
Caronia LM, Dwyer AA, Hayden D, Amati F, Pitteloud N, Hayes FJ. Abrupt decrease in serum testosterone levels after an oral glucose load in men: implications for screening for hypogonadism. Clin Endocrinol (Oxf). 2013;78:291–6.
doi: 10.1111/j.1365-2265.2012.04486.x
Van de Velde F, Reyns T, Toye K, Fiers T, Kaufman JM, T’Sjoen G, Lapauw B. The effects of age and obesity on the postprandial dynamics of serum testosterone levels in men. Clin Endocrinol (Oxf). 2020;92:214–21.
doi: 10.1111/cen.14141
Spratt DI, O’Dea L, Schoenfeld D, Butler J, Narashimha H, Rao P, Crowley WF. Neuroendocrine-gonadal axis in men: frequent sampling of LH, FSH and testosterone. Am J Physiol. 1988;254:E658–66.
Brambilla DJ, O’Donnell AB, Matsumoto AM, McKinlay JB. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol (Oxf). 2007;67:853–62.
doi: 10.1111/j.1365-2265.2007.02976.x
Monaghan PJ, Keevil BG, Stewart PM, Trainer PJ. Case for the wider adoption of mass spectrometry-based adrenal steroid testing, and beyond. J Clin Endocrinol Metab. 2014;99:4434–7.
doi: 10.1210/jc.2014-2258
Taylor AE, Keevil B, Huhtaniemi IT. Mass spectrometry and immunoassay: how to measure steroid hormones today and tomorrow. Eur J Endocrinol. 2015;173:D1–12.
doi: 10.1530/EJE-15-0338
Hillebrand JJ, Wickenhagen WV, Heijboer AC. Improving science by overcoming laboratory pitfalls with hormone measurements. J Clin Endocrinol Metab. 2021;106:E1504–12.
doi: 10.1210/clinem/dgaa923
Livingston M, Downie P, Hackett G, Marrington R, Heald A, Ramachandran S. An audit of the measuremet and reporting of male testosterone levels in UK clinical biochemistry laboratories. Int J Clin Pact. 2020:00:e13607. https://doi.org/10.1111/ijcp.13607 .
Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, Lacroix I, Somma-Delpero C, Boudou P. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem. 2003;49:1381–95.
doi: 10.1373/49.8.1381
Handelsman DJ. Mass spectrometry, immunoassay and valid steroid measurements in reproductive medicine and science. Hum Reprod. 2017;32:1147–50.
doi: 10.1093/humrep/dex078
Huhtaniemi IT, Tajar A, Lee DM, O’Neill TW, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean MEJ, Pendleton N, PunabM, Silman AJ, Vanderschueren D, Forti G. Wu FCW and the EMAS Group. Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. Eur J Endocrinol. 2012;166:983–91.
doi: 10.1530/EJE-11-1051
Haring R, Baumeister SE, Nauck M, Völzke H, Keevil BG, Brabant G, Wallaschofski H. Testosterone and cardiometabolic risk in the general population - the impact of measurement method on risk associations: a comparative study between immunoassay and mass spectrometry. Eur J Endocrinol. 2013;169:463–70.
doi: 10.1530/EJE-13-0222
Vesper HW, Bhasin S, Wang C, Tai SS, Dodge LA, Singh RJ, Nelson J, Ohorodnik S, Clarke NJ, Salameh WA, et al. Interlaboratory comparison study of serum testosterone [corrected] measurements performed by mass spectrometry methods. Steroids. 2009;74:498–503. (doi: https://doi.org/10.1016/j.steroids.2009.01.004 ).
doi: 10.1016/j.steroids.2009.01.004
Fiers T, Wu F, Moghetti P, Vanderschueren D, Lapauw B, Kaufman JM. Reassessing free testosterone calculation by liquid chromatography-tandem-mass-spectrometry direct equilibrium dialysis. J Clin endocrinol Metab. 2018;103:2167–74.
doi: 10.1210/jc.2017-02360
Mendel CM. The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev. 1989;10:232–74.
doi: 10.1210/edrv-10-3-232
Hammond GL. Plasma steroid-binding proteins: primary gatekeepers of steroid hormone action. J Endocrinol. 2016;230:R13–25.
doi: 10.1530/JOE-16-0070
Laurent MR, Hammond GL, Blokland M, Jard´ı F, Antonio L, Dubois V, Khalil R, Sterk SS, Gielen E, Decallonne B, Carmeliet G, Kaufman JM, Fiers T, Huhtaniemi IT, Vanderschueren D, Claessens F. Sex hormone-binding globulin regulation of androgen bioactivity in vivo: validation of the free hormone hypothesis. Sci Rep. 2016;6:35539.
doi: 10.1038/srep35539
Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666–72.
doi: 10.1210/jcem.84.10.6079
Antonio L, Wu FC, O’Neill TW, Pye SR, Ahern TB, Laurent MR, Huhtaniemi IT, Lean ME, Keevil BG, Rastrelli G, Forti G, Bartfai G, Casanueva FF, Kula K, Punab M, Giwercman A, Claessens F, Decallonne B, Vanderschueren D. European Male Ageing Study Study Group. Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone. J Clin Endocrinol Metab. 2016;101:2647–57.
doi: 10.1210/jc.2015-4106
Rastrelli G, O’Neill TW, Ahern T, Gyorgy B, Casanueva FF, Forti G, Keevil B, Giwercman A, Han TS, Slowikowska-Hilczer J, Lean MEJ, Pendleton N, Punab M, Antonio L, Tournoy J, Vanderschueren D, Maggi M, Huhtaniemi IT, Wu FCW. EMAS study group. Symptomatic androgen deficiency develops only when both total and free testosterone decline in obese men who may have incident biochemical secondary hypogonadism: prospective results from the EMAS. Clin Endocrinol (Oxf). 2018;89:459–69.
doi: 10.1111/cen.13756
Liu Z, Liu J, Shi X, Wang L, Yang Y, Tao M, Fu Q. Comparing calculated free testosterone with total testosterone for screening and diagnosing late onset hypogonadism in aged males: a cross-sectional study. J Clin Lab Anal. 2017;31:e22073.
doi: 10.1002/jcla.22073
Fiers T, Delanghe J, T’Sjoen G, Van Caenegem E, Wierckx K, Kaufman JM. A critical evaluation of salivary testosterone as a method for the assessment of serum testosterone. Steroids. 2014;86:5–9.
doi: 10.1016/j.steroids.2014.04.013
Goldman AL, Bhasin S, Wu FCW, Krishna M, Matsumoto AM, Jasuja R. A reappraisal of testosterone’s binding in circulation: physiological and clinical implications. Endocr Rev. 2017;38:302–24.
doi: 10.1210/er.2017-00025
Södergård R, Bäckström T, Shanbhag V, CarstensenH. Calculation of free and bound fractions of testosterone and estradiol-17b to human plasma proteins at body temperature. J Steroid Biochem. 1982;16:801–10.
doi: 10.1016/0022-4731(82)90038-3
Mazer NA. A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol: with illustrative examples from male and female populations. Steroids. 2009;74:512–9.
doi: 10.1016/j.steroids.2009.01.008
Ly LP, Handelsman DJ. Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoassays. Eur J Endocrinol. 2005;152:471–8.
doi: 10.1530/eje.1.01844
Zakharov MN, Bhasin S, Travison TG, Xue R, Ulloor J, Vasan RS, Carter E, Wu F, Jasuja R. A multi-step, dynamic allosteric model of testosterone’s binding to sex hormone binding globulin (published correction appears in. Mol Cell Endocrinol. 2017;454:167). Mol Cell Endocrinol. 2015;399(C):190–200.
Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E, Wang PY, Nielson C, Wu F, Tajar A, Labrie F, Vesper H, Zhang A, Ulloor J, Singh R, D’Agostino R, Vasan RS. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96:2430–9.
doi: 10.1210/jc.2010-3012

Auteurs

Jean-Marc Kaufman (JM)

Department of Endocrinology, Ghent University Hospital, Ghent, Belgium. Jean.kaufman@ugent.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH